Beijing Continent Pharmaceuticals Co., Ltd. was founded in 2002, and is an innovative drug development enterprise focused on organ fibrosis diseases, integrating research and development, production, and commercialization. Beijing Continent is a holding subsidiary of Gyre Therapeutics, Inc., a NASDAQ-listed company (stock ticker: GYRE).
As a pioneer in the field of organ fibrosis, the company's flagship product, the Class 1.1 new drug ETUARY® (Pirfenidone Capsules), is one of only two approved drugs recommended by guidelines for the treatment of idiopathic pulmonary fibrosis (IPF) worldwide. It is also the first innovative drug for IPF treatment in China, filling a gap in this field after its successful launch in 2014. The company's next key product—F351 (Hydronidone) for the treatment of liver fibrosis—has been recognized as a "Breakthrough Therapy Drug" by the Drug Evaluation Center, and is expected to become the first approved drug worldwide for the treatment of fibrosis associated with chronic hepatitis B (CHB).
The company will enrich and advance its product pipeline by leveraging the complete experience accumulated from the independent development to commercial success of ETUARY®, gradually expanding its therapeutic areas to other organ fibrosis, researching and developing innovative drugs for pulmonary fibrosis, liver fibrosis, and renal fibrosis, bringing new hope to more patients with organ fibrosis.
Beijing Continent Pharmaceuticals Co., Ltd. was founded in 2002, and is an innovative drug development enterprise focused on organ fibrosis diseases, integrating research and development, production, and commercialization. Beijing Continent is a holding subsidiary of Gyre Therapeutics, Inc., a NASDAQ-listed company (stock ticker: GYRE).
As a pioneer in the field of anti-organ fibrosis, the company's flagship product, Class 1.1 new drug ETUARY® (Pirfenidone Capsule), is one of only two approved drugs for IPF treatment worldwide. It is the first innovative drug approved for IPF in China, filling the gap in the IPF treatment field after its successful launch in 2014. F351 (Hydronidone) is the company's key product for the next stage, granted a Breakthrough Therapy designation as a liver fibrosis treatment by the CDE, and is expected to be the first approved drug for the treatment of liver fibrosis associated with CHB.
The company will enrich and boost its product pipeline by utilizing the successful and complete experience accumulated from in-house development to commercialization of ETUARY®. We are expanding our therapeutic field to other organ fibrosis, researching and developing treatments for pulmonary fibrosis, liver fibrosis, and renal fibrosis to bring new hope to patients with organ fibrosis.
What does Beijing Continent Pharmaceuticals Co., Ltd. require? Who is Continent hiring? Continent recruitment: 销售类占比最多占85.1%，其次是计算机/网络/技术类占48.1%. What education can get in at Continent? 大专占比最多占75.1%，其次是本科占12.5%. High education required at Continent? 硕士占0.3%. Work experience required at Continent? 1-3年占比最多占50.5%，其次是不限占20.4%. Where are the job locations at Continent? 广州占比最多占7.6%，其次是北京占6.6%. Based on job postings from the past year, for reference only.
Provided by
Congratulations, submitted successfully!
Your edit is under review. You will be notified by email within 1 business day.
Submission failed.
Help others learn about this company, add my impression of this company»
Log in with the following accounts to save your follows
Jobui does not provide an APP. Please follow our WeChat official account.
